SF - Stifel Financial Corp
SKYRIZIÂ (risankizumab) and RINVOQÂ (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2
ST. LOUIS, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced that it has made a strategic minority investment in Meow Technologies, Inc. (“Meow”), one of the leading business banking fintechs in the United States, and has entered into a services agreement under which Stifel will offer through its subsidiary bank, Stifel Bank, a white-label version of Meow's treasury management platform to its commercial banking clients, with an initial focus on Venture and Fund Banking. Under the agreement, Stifel will have access to Meow's current and forward capabilities, giving Stifel clients a modern digital experience for managing cash, payments, cards, and day-to-day treasury operations across operating companies and multi-entity fund structures.
ST. LOUIS, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) will release its third quarter financial results before the market opens on Wednesday, October 21, 2026. The company will host a conference call to review the results at 9:30 a.m. Eastern time that same day. The conference call may include forward-looking statements.
Stifel Financial (NYSE: SF - Get Free Report) and Morgan Stanley Direct Lending Fund (NYSE: MSDL - Get Free Report) are both finance companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations and valuation. Risk and Volatility Stifel Financial
Faron Pharmaceuticals Limited (AIM:FARN) retained Stifel's ‘buy' rating and €2.50 price target after its research and development day strengthened the case for bexmarilimab, though the broker still awaits decisive BEXERA results. The bank said the event increased its confidence in the programme without disclosing major new efficacy data or materially changing its investment thesis.
Argent Capital Management LLC acquired a new stake in shares of Stifel Financial Corporation (NYSE: SF) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 199,915 shares of the financial services provider's stock, valued at approximately $14,002,000. Argent Capital Management LLC owned
This biotech stock could soar 30% or more over the next 12 months if some analysts are right.
Stifel Financial showed some of the disadvantages of the mid-market in the current environment in advisory that favors larger ticket deals. On the other hand, there have been improvements in the equity capital markets (ECM) environment that have managed to support the business sequentially and YoY despite Hormuz. AM tends to be quite resilient, and indeed growth in client assets, at least YoY, has allowed for decent growth here.
BALTIMORE, Sept. 30, 2026 /PRNewswire/ -- 1919 Investment Counsel, LLC ("1919"), a subsidiary of Stifel Financial Corp. ("Stifel"), is proud to announce its inclusion in Barron's 2026 Top 100 RIA Firms list.
Stifel, the broker, has kept its ‘buy' rating and CHF25 target price on Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0), the Swiss neuromuscular drugmaker, after first-half group revenue doubled to CHF48.3 million. The company left its 2026 guidance of CHF80 million to CHF90 million unchanged.
ST. LOUIS, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today reported selected operating results for August 31, 2026, to provide timely information to investors on certain key performance metrics. Due to the limited nature of this data, a consistent correlation to earnings should not be assumed.
Stifel Financial announces the addition of three senior leaders to its Venture Banking business, further solidifying its presence across the East Coast.
VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Stifel Financial Corporation (NYSE: SF) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 10,000 shares of the financial services provider's stock, valued at approximately $698,000. A number of
Amundi reduced its holdings in shares of Stifel Financial Corporation (NYSE: SF) by 68.7% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 153,885 shares of the financial services provider's stock after selling 337,532 shares during the period. Amundi
NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Keefe, Bruyette & Woods, Inc., a leading specialist investment bank to the financial services and fintech sectors, and a wholly owned subsidiary of Stifel Financial Corp. (NYSE: SF), announces the upcoming index rebalancing for the third quarter of 2026.
MISSION Group (LSE:TMG) drew a bullish call from Stifel, which argued the marketing group's valuation overlooks a profit recovery driven by cost cuts and agency consolidation. The shares traded at 23.85p, up 4%, while the broker initiated coverage with a 'buy' rating and a 57p target, more than double the share price.
ST. LOUIS & LONDON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced the appointments of Conor Daly and Jim Franz as Co-Heads of Leveraged Finance Sales in Europe, further strengthening the firm's global Fixed Income platform.
Canada Pension Plan Investment Board purchased a new position in Stifel Financial Corporation (NYSE: SF) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 93,950 shares of the financial services provider's stock, valued at approximately $6,555,000. Canada Pension Plan Investment Board
ST. LOUIS, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today reported selected operating results for July 31, 2026, to provide timely information to investors on certain key performance metrics. Due to the limited nature of this data, a consistent correlation to earnings should not be assumed.
Stifel has reiterated its 'buy' rating on Faron Pharmaceuticals Limited (AIM:FARN), the Finnish biotech, maintaining a price target of €2.50 after the company's interims, which showed the company well-funded to push on with value-accretive work in the clinic. The stock closed at €0.48 on 25 August, implying upside of 418.1% to the target price.